Casdatifan Shows Activity Across Kidney Cancer Cohorts
Arcus disclosed new ARC-20 cohort results for the HIF-2α inhibitor casdatifan in clear-cell renal carcinoma. The breadth of activity supports further randomized trials, but comparisons with historical regimens cannot establish competitive superiority.
